Patents by Inventor Maria EKBLAD

Maria EKBLAD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOPICAL FORMULATION
    Publication number: 20220273765
    Abstract: The present invention concerns a composition comprising a peptide, a saccharide and a lipid vehicle, which is suitable for topical delivery.
    Type: Application
    Filed: April 24, 2020
    Publication date: September 1, 2022
    Applicant: Follicum AB
    Inventors: Åke Lindahl, Jan Alenfall, Maria Ekblad
  • PEPTIDE FRAGMENTS FOR TREATMENT OF DIABETES
    Publication number: 20220002343
    Abstract: The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptide fragments.
    Type: Application
    Filed: November 7, 2019
    Publication date: January 6, 2022
    Applicant: Follicum AB
    Inventors: Jan Alenfall, Maria Ekblad, Pontus Dunér
  • Compounds useful as S100-inhibitors
    Patent number: 9771372
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 26, 2017
    Assignee: Active Biotech AB
    Inventors: Ulf Wellmar, David Liberg, Maria Ekblad, Marie Bainbridge, Stephen East, Jonathan Hargrave, Natacha Prevost
  • NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS
    Publication number: 20170204098
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 20, 2017
    Inventors: Ulf WELLMAR, David LIBERG, Maria EKBLAD, Marie BAINBRIDGE, Stephen EAST, Jonathan HARGRAVE, Natacha PREVOST